Status: Not yet recruiting
Observational Registry Evaluating the Clinical Impact of the Blood-Based Biomarker Test for Early-Stage Pancreatic Ductal Adenocarcinoma
The goal of this observational registry is to examine the changes made to pancreatic cancer surveillance management following the real-world clinical use of PancreaSure testing among individuals at increased risk for pancreatic ductal adenocarcinoma. The main question it aims to answer is, does surveillance management and intent change following the return of PancreaSure binary results.
Participants needed: 400
Trial details
Age: 45+Biological sex: AllType: ObservationalSponsor: Immunovia, Inc.Updated: Sep 4, 2026Duration: 2 Years
Eligibility criteria
Able to provide informed written consent and complete the survey in English or S... [+7]
Prior diagnosis of PDAC or other active malignancy within 3 years (except non-me... [+2]